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Irisin is a newly discovered exercise-mediated myokine which regulates energy metabolism and has been the subject
of much recent research. Irisin plays an important role in metabolic diseases making it a potential new target to combat
obesity and its associated disorders, such as T2DM. However, the results of several recent studies investigating the
effects of irisin have been controversial. The present review will introduce the discovery of irisin, the role of irisin in
metabolic disorders, possible mechanisms, and unanswered questions for future research.
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Irisin is a newly discovered exercise-mediated myokine
which regulates energy metabolism by inducing brown-
ing of white adipose tissue and thus dissipates chemical
energy in the form of heat. Bostrom et al. [1] revealed
that exercise stimulates PPAR-γ co-activator-1α (PGC-
1α), which in turn upregulates its downstream target fi-
bronectin type III domain containing 5 (FNDC5), there-
after the C-terminus is cleaved and the remaining 112
amino acid peptide is referred to as irisin. By increasing
the mRNA expression of UCP1 and Cidea, irisin causes
browning of primarily subcutaneous and visceral adipose
tissue and thereby induces thermogenesis. However, Wu
et al. [2] reported that only part of the subcutaneous adi-
pose tissue inverts into brown adipose tissue (BAT), with
a substantial portion not demonstrating features consist-
ent with classical white adipose tissue (WAT) or BAT
which they refer to it beige adipose tissues.
Irisin has gained great interest as a potential new tar-
get to combat obesity and its associated disorders, such
as type 2 diabetes mellitus (T2DM). For Bostrom et al.
[1] reported that moderate increases in circulating irisin
levels augments energy expenditure, protects against
diet-induced weight gain and alleviates insulin resist-
ance. Numerous studies focus on the association of irisin* Correspondence: qushencn@hotmail.com
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irisin in obesity, diabetes, and other metabolic diseases.Irisin in obesity and metabolic syndrome
Irisin has initially been described as a protective factor
against diet-induced weight gain, mediated by browning
of WAT and thus increased energy expenditure [1]. Many
subsequent studies have investigated the association of cir-
culating irisin with obesity in humans (summarized in
Table 1).
Several studies have investigated the relationship be-
tween circulating irisin and body mass index (BMI).
Huh et al. [3] reported in a cross-sectional study of 117
healthy middle-aged women with BMI ranging from
20.0 to 47.7 kg/m2, circulating irisin had positive associ-
ations with fat-free mass and a positive trend with BMI.
Stengel et al. [4] performed a study including anorexia
nervosa patients, normal weight control subjects, and
morbidly obese patients, providing a broad spectrum of
body weights. They found that obese patients have
higher circulating irisin levels compared with normal
weight controls and anorexic patients, and irisin has a
positive correlation with body weight and BMI. Simi-
larly, Pardo et al. [5] reported that in 145 female
patients, including anorexia nervosa patients, obese pa-
tients, and healthy normal weight subjects, the plasma
irisin levels are significantly elevated in the obese pa-
tients compared with the anorexia nervosa patients and
normal weight subjects, and irisin also positively corre-
lated with body weight, BMI, and fat mass. Liu et al. [6]his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The association between irisin levels and obesity
Population Group size Study design
Positive correlation between irisin levels and obesity
Huh et al. [3] Healthy middle-aged women with wide range of BMI 117 Cross-sectional
Stengel et al. [4] Anorexia nervosa patients, normal weight control subjects, and morbidly obese patients 40 Cross-sectional
Pardo et al. [5] Anorexia nervosa patients, normal weight control subjects, and morbidly obese patients 145 Cross-sectional
Liu et al. [6] Diabetic subjects and non-diabetic subjects 156 Cross-sectional
Huh et al. [3] Subjects undergoing gastric banding or gastric bypass surgery 14 Interventional
De la Iglesia et al. [13] Subjects following an 8-week hypocaloric dietary strategy 93 Interventional
Crujeiras et al. [8] Obese patients undergoing a weight loss program consisting
of 8 weeks of a hypocaloric diet and follow-up at 16-weeks
94 Interventional
Negative correlation between irisin levels and obesity
Moreno-Navarrete et al. [10] Non-diabetic subjects 69 Cross-sectional
Choi et al. [11] NGT subjects and new-onset T2DM subjects 208 Cross-sectional
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correlated with BMI. Their group also reported that in
patients with T2DM and renal insufficiency, irisin levels
correlated with BMI, fat mass, and percentage of fat
mass [7]. Additional studies (Crujeiras et al. [8] & Park
et al. [9]) have also shown that plasma irisin levels are
positively correlated with weight, BMI, waist circumfer-
ence, and fat mass.
However, the results from other studies have been
controversial. Moreno-Navarrete et al. [10] studied a
subgroup of 69 non-diabetic subjects with BMI 27.61 ±
3.8, and reported that circulating irisin decreased in as-
sociation with obesity. In fact, they showed that circulat-
ing irisin was negatively associated with BMI, percent fat
mass, and waist to hip ratio. Choi et al. [11] found that
plasma irisin was negatively correlated with BMI in a
study population including 104 subjects with normal
glucose tolerance and 104 subjects with new-onset T2D.
Sanchis-Gomar et al. [12] did not find a positive or
negative correlation between circulating irisin levels and
BMI.
The discrepancies in the above mentioned studies may
be due to different populations analyzed in the studies,
as some included obese subjects with metabolic diseases,
which may influence plasma irisin levels.
Studies looking at patients undergoing interventions
provide further evidence supporting the positive correl-
ation between BMI and circulating irisin levels. Blood
samples were collected at baseline and 6 months after
surgery in a subgroup of 14 obese subjects who were
undergoing gastric banding or gastric bypass surgery [3].
Circulating irisin levels decreased significantly after 6
months, which was accompanied by significant weight
loss. De la Iglesia et al. [13] studied ninety-three Cauca-
sian adults diagnosed with metabolic syndrome, who
followed an 8-week hypocaloric dietary strategy. They
found plasma irisin levels were significantly reduced atthe end of the study accompanying the weight loss.
Crujeiras et al. [8] reported in a group of 94 obese pa-
tients (BMI 35.66 ± 4.5 kg/m2), after a weight loss pro-
gram consisting of 8 weeks of a hypocaloric diet and
follow-up at 16-weeks. Irisin levels decreased paralleling
body weight reduction after caloric restriction at 8
weeks, and returned to baseline levels at 24 weeks in
those patients who regained the lost weight.
Additionally, a lower fat mass may also have contribu-
tied to the lower irisin levels. Roca-Rivada et al. [14]
found secretion of irisin was higher from white adipose
tissues of diet-induced obese rats compared to lean con-
trols, suggesting that adipose tissue, especially in obesity,
was an important source of irisin. Consistent with this
view, some studies also found circulating irisin was posi-
tively correlated with fat mass in human [4,5,8-10,15,16].
In summary, despite some controversy, it is generally
believed that there is a positive correlation of circulating
irisin with obesity, which is in apparent conflict with the
proposed anti-obesity effect of irisin. A possible explan-
ation which could reconcile the controversial data may
be that irisin acts as a physiological protective factor
against obesity mediated by the browning of WAT and is
thus increased in compensation for increasing body
mass. In pathological states of morbidity obesity, physio-
logical irisin cannot maintain the balance of energy stor-
age and expenditure, and additional irisin is secreted
from skeletal muscle, and even adipose tissue can pro-
duce irisin as compensation for dramatically increased
fat storage.
Metabolic syndrome (MetS) is associated with a num-
ber of metabolic disorders and may be caused by obesity,
especially central obesity.
Hee et al. [16] reported that baseline irisin levels are sig-
nificantly higher in subjects with MetS than in subjects
without MetS, while Yan et al. [17] reported that circulat-
ing irisin levels are significantly reduced in subjects with
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population recruited in these studies, as the study from
Hee included subjects with MetS with high BMI making it
the most important factor while the study from Yan
included subjects with central obesity making glucose
homeostasis and insulin resistance (IR) the major factors
(discussed below).
Irisin in DM and glucose homeostasis
A moderate increase in circulating irisin levels augmented
energy expenditure, not only reducing weight gain due to
a high-fat diet, but also improving diet induced IR [1]. As
irisin is a novel myokine secreted in response to PGC-1α
activation. Studies suggest that PGC-1α is important for
mitochondrial homeostasis for it regulates mitochondrial
biogenesis and oxidative metabolism, and mitochondrial
function also plays a role in IR. Furthermore, expression
and activity of PGC1-α are lower in patients with T2DM
[18-20].
Choi et al. [11] compared serum irisin levels in new-
onset T2DM patients with normal glucose tolerance
(NGT) controls, and found that serum irisin levels are
significantly decreased in the new-onset T2DM group.
Moreover, increased irisin levels are associated with re-
duced odds of newly diagnosed T2DM. Xiang et al. [21]
reported that in newly diagnosed T2DM subjects, serum
irisin concentrations are significantly lower than that in
controls. Kurdiova et al. [22] also reported similar results
in drug-naive T2DM subjects. This phenomenon is also
observed in long-term T2DM patients which has been
reported in several other studies [6,10,23].
Yuksel et al. [24] performed a case–control study of 20
women with gestational diabetes mellitus (GDM) and 20
pregnant women without GDM. Maternal serum irisin
levels were significantly lower at the time of birth in
women with GDM compared to controls, while cord
blood irisin levels are not significantly different. Kuzmicki
et al. [25] also found that serum irisin concentration was
significantly lower in patients with GDM compared with
NGT subjects; but the significant difference between the
two groups disappeared 3 months after delivery. However
two other studies reported conflicting results. Ebert et al.
[26] found that in GDM patients, circulating irisin levels
were significantly higher than that in healthy, pregnant,
gestational age-matched controls after delivery, but did
not differ during pregnancy. Piya et al. [27] studied preg-
nant women undergoing elective caesarean-section, and
reported that in obese and GDM subjects, fasting serum
irisin before caesarean section was significantly higher
compared with controls, after adjusting for BMI, lipids,
and blood glucose.
In addition to the above findings, the association be-
tween irisin and glucose homeostasis has also reported.
These results have also been controversial. Choi et al. [11]found that serum irisin was significantly negatively corre-
lated with 2 h plasma glucose and hemoglobin A1c
(HbA1c). Furthermore, multiple regression analysis showed
that 2 h plasma glucose was an independent variable influ-
encing serum irisin levels. Yan et al. [17] also reported in
obese Chinese adults, serum irisin was significantly nega-
tively associated with fasting insulin and HbA1c. On the
other hand, Liu et al. [6] found that circulating irisin was
significantly positively correlated with fasting blood glucose.
Hee Park et al. [16] also reported that circulating irisin was
associated positively with fasting glucose and homeostasis
model assessment of insulin resistance (HOMA-IR). Sesti
et al. [28] found that irisin levels were positively correlated
with fasting and 2 h post-load insulin levels, and were nega-
tively correlated with insulin-stimulated glucose disposal,
and insulin clearance. However, Stengal et al. [4] did not
find an association between serum irisin and blood glucose
levels, but found that serum irisin was positively correlated
with insulin levels.
Crujeiras et al. [29] reported in a study of 136 obese pa-
tients who followed an eight-week hypocaloric diet that
after a successful dietary intervention, 50% of the patients
who regained the lost weight during the follow-up period
were categorized as insulin resistant (HOMA-IR ≥ 2.5)
compared with only 25% of patients who maintain the
weight loss. And increased risk of IR during the follow-up
period was related to high irisin levels at baseline.
Al-Daghri et al. [30] conducted a study in a cohort of
153 Saudi Arabian children, and found that girls have
higher circulating irisin levels than boys. There was a
significant correlation between circulating irisin and fast-
ing blood glucose. And in girls, but not in boys,
HOMA-IR correlated negatively with irisin levels.
In addition, serum irisin was also associated with glu-
cose homeostasis in pregnancy. Kuzmicki et al. [25] re-
ported in pregnant patients, irisin concentration was
negatively associated with 2 h glucose levels. In the
women with NGT, irisin concentration was negatively
associated with 2 h insulin level and HOMA-IR. This
phenomenon was also reported by Yuksel et al. [24] that
serum irisin level is negatively correlated with HOMA-
IR in pregnancy. However, Ebert et al. [26] found that
fasting insulin was positively associated with serum irisin
during pregnancy.
In conclusion, circulating irisin levels are lower in both
newly-diagnosed and long-term T2DM, which indicates
that irisin can be a predictor of T2DM (Table 2). The
decrease in irisin may due to lower PGC-1α expression
and activity. However for GDM, results were not con-
sistent, this may due to the fact that irisin was detected
at different times during pregnancy or after delivery.
The association between irisin and glucose homeostasis
was confirmed by several studies, indicating that irisin
may be a predictor and protective factor for developing
Table 2 Level of irisin in other pathological condistions
Pathological conditions Level of irisin Reference
Newly diagnosed T2DM Decrease Choi et al. [11] Xiang et al. [21] Kurdiova et al. [22]
Long-term T2DM Decrease Liu et al. [6] Moreno-Navarrete et al. [10] Zhang et al. [23]
GDM Decrease Yuksel et al. [24] Kuzmicki et al. [25]
No difference Ebert et al. [26]
MetS Increase Hee et al. [16]
Decrease Yan et al. [17]
NAFLD Decrease Zhang et al. [34] Polyzos et al. [35]
Increase Choi et al. [36]
PCOS Increase Chang et al. [37]
CKD Decrease Liu et al. [7] Wen et al. [38] Ebert et al. [39]
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concerned, still remains controversial. Different popula-
tions studied may partially explain the different results.
For Choi et al. [11] and Yan et al. [17], the populations
included individuals with little or no IR. However for
Liu et al. [6] and Hee Park et al. [16], the populations
may have had more severe IR and irisin was increased in
response to the deterioration of insulin sensitivity.
Irisin in other metabolic disorders
Besides obesity and T2DM, many studies assessed the
role of irisin in other metabolic diseases (Table 2).
Earlier studies have shown that non-alcoholic fatty
liver disease (NAFLD) and polycystic ovary syndrome
(PCOS) are associated with MetS and its components
[31,32]. De la Iglesia et al. [13] reported that in MetS
subjects, the depletion of irisin after a weight loss pro-
gram significantly correlated with changes in total chol-
esterol, total cholesterol/high-density lipoprotein (HDL)
cholesterol ratio, low-density lipoprotein (LDL) choles-
terol and apolipoprotein B, independently of changes in
body weight. Panagiotou et al. [33] reported that in sub-
jects with high cardiovascular risk, irisin was negatively
associated with HDL cholesterol and large HDL particles
after adjusting for age, sex, and race.
Zhang et al. [34] found that serum irisin levels were
reduced in obese adults with NAFLD. Serum irisin levels
were reduced gradually with the increase of intrahepatic
triglyceride content. Higher serum irisin levels were as-
sociated with preferable triglyceride levels. Additionally
serum irisin levels were independently associated with
liver fat. Polyzos et al. [35] also found that serum irisin
levels were significantly decreased in patients with
NAFLD and non-alcoholic steatohepatitis (NASH) com-
pared with lean controls, but do not differ between pa-
tients with NAFLD and NASH. This difference remains
significant after adjustment for BMI or waist circumfer-
ence, gender, age, and IR. However, Choi et al. [36]
found that in 355 health screen examinees, the subjectswith NAFLD had significantly higher irisin levels than
the subjects without NAFLD. These results suggest that
irisin may play an important role in lipid metabolism
and thus in the development of NALFD, and the mech-
anism behind it needs further researches.
Chang et al. [37] reported that serum irisin levels in
PCOS patients are significantly elevated as compared to
those of controls. Remarkably, levels of fasting irisin
remained significantly elevated in PCOS without MetS
risk factors and healthy-weight PCOS patients when
compared to matched controls. This indicates that irisin
might be an independent factor that contributes to the
development of PCOS and may also represent a novel
PCOS biomarker.
Liu et al. [7] reported circulating irisin was signifi-
cantly decreased in T2DM with renal insufficiency and
the reduction in irisin was most pronounced in stage 5
chronic kidney disease (CKD) patients. Wen et al. [38]
found that irisin levels were significantly decreased in
patients with stage 5 CKD than in age- and sex-matched
normal subjects. The decrease in irisin levels was in-
versely correlated with the levels of blood urea nitrogen
and creatinine. Ebert et al. [39] studied a patient popula-
tion with stage 1 to 5 CKD, and found that serum irisin
levels significantly decreased with increasing CKD stage
and are lowest in patients with stage 5 CKD. These re-
sults suggest that irisin is associated with renal function
and that irisin may not be renally excreted. The possible
mechanism may involve negative feedback on myocytes
by increasing serum creatinine resulting in decreased iri-
sin secretion.
In addition, Anastasilakis et al. [40] studied irisin levels in
postmenopausal women with low bone mass and age-
matched controls. They found that serum irisin levels were
not significantly different between women with or without
low bone mass and are not affected by either denosumab or
teriparatide treatment for 3 months. However irisin levels
were lower in women with than without previous osteopor-
otic fractures, and were negatively associated parathyroid
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tively associated with bone density Z-scores, volumetric
bone mineral density (total and trabecular), stiffness, and
failure load in 85 adolescent women. These results did not
reveal the association between irisin and bone metabolism
clearly, and further researches are needed.
Summary
The discovery of irisin and its role in metabolic diseases
may reveal a new target for obesity and its related dis-
eases, like T2DM, and NAFLD, although different re-
search groups have reported conflicting results. There are
still many questions to be answered. Most importantly,
the mechanism of action of irisin in metabolic diseases re-
mains incompletely understood. Only once the underlying
mechanisms have been revealed, can we explain the dis-
crepancies between reported results, and understand the
true role that irisin plays in a variety of metabolic diseases.
Other gaps to be filled in further studies include identifi-
cation of the irisin receptor, the molecular pathways regu-
lating irisin, and other functions of irisin.
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